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Abstract: PRDM1 (BLIMP1) is a transcription repressor protein shown to be involved in B-cell differentiation into
plasma cells. Marginal zone lymphomas (MZL) and lymphoplasmacytic lymphomas (LPL) are B cell lymphomas that
both show some degree of plasmacytic differentiation and thus can sometimes constitute a difficult differential
diagnosis. In this study, we investigated if MZL and LPL have abnormalities in the expression of PRDM1 beta and
if there are any differences in expression between these two entities. After interrogating 42 samples (15 marginal
zone lymphomas, 9 lymphoplasmacytic lymphomas, 3 follicular lymphomas, and 13 normal/control samples), we
have found that a significant percentage of MZL and LPL cases harbor abnormalities (67% and 44%, respectively)
involving the PRDM1-β transcript (P=0.004). By immunohistochemistry, PRDM1 positive staining (>5%) was more
common in MZL. We conclude that PRDM1-β may play a role in the pathogenesis of these low-grade lymphomas
with plasmacytic differentiation.
Keywords: PRDM1, marginal zone lymphoma, lymphoplasmacytic lymphoma

Introduction
Positive regulatory domain containing 1 with
zinc-finger domain (PRDM1/BLIMP) located on
chromosome 6q21-22.1 has been cited as the
“master regulator” of B cell and plasma cell differentiation. PRDM1 encodes a 98 kDa protein
that represses beta-interferon gene expression
via PRDI promoter binding. Alternative splicing
leads to 2 variant isoforms: PRDM1α, which is
a tumor suppressor and PRDM1β, which lacks
the ability to repress transcription. Compared
to PRDM1α, PRDM1β lacks exons 1-3 and the
amino-terminal 101 amino acids. It also lacks
the PR domain of PRDM1α. Both α and β isoforms have shown to be involved in B cell differentiation into plasma cells [1]. More specifically, PRDM1 has been shown to up-regulate
syndecan-1 (CD138) in transfected B cell lymphoma cell lines [2]. Furthermore, PRDM1β is
expressed in germinal center B-cells that have
committed to plasmacytic differentiation [3].
PRDM1 expression is repressed by BCL-6 in

mature B cells and promotes plasmacytic differentiation by repressing PAX5 and allowing
expression of XBP-1 [4, 5].
PRDM1 was first described in 1991 as a novel
repressor of beta interferon [6]. It was formally
described in 1994 as B lymphocyte induced
maturation protein (BLIMP1), a transcription
repressor protein. There have been a number of
studies looking at the role PRDM1 plays in various B-lineage lymphoid malignancies. Several
papers have described the role of PRDM1
mutations in the pathogenesis of diffuse large
B-cell lymphomas (DLBCL) [7, 8]. Furthermore,
PRDM1 mutations are associated with increased chemotherapy resistance to regimens
lacking Rituxan [9]. Previous publications also
show a relationship between treatment response and PRDM1-β expression levels in mantle cell lymphoma (MCL) [10]. In multiple myeloma cases, PRDM1 is reported to be functionally
impaired [11]. PRDM1 has also been shown to
be downregulated in other lymphomas such as

PRDM1 in MZL and LPL
Table 1. Demographic and sample characteristics
Number
of cases
FL
LPL
MZL
NL/Other

3
9
15
12

Mean Percent
involvement
by FC (Range)
62 (57-69) 2:1
30% (<1%-51%)
62 (51-79) 2:7
10% (<1%-46%)
67 (50-87) 5:10 31.5% (1.2%-86%)
14-73
N/A
N/A
Mean Age Sex
(Range) (F:M)

FC = Flow Cytometry; FL = Follicular Lymphoma, LPL = lymphoplasmacytic lymphoma, MZL = marginal zone lymphoma, NL = normal
control.

NK/T cell lymphoma [12] and anaplastic large T
cell lymphoma [13].
Marginal zone lymphoma (MZL) comprises
three major classes of lymphoproliferative diseases, namely splenic MZL, nodal MZL, and
extranodal MZL (MALT lymphomas) [14]. Together they constitute 5-17% of all non-Hodgkin
lymphomas and are generally considered indolent neoplasms. However, when stratified by
risk levels, 5-year overall survival ranges from
56-100% [15]. Lymphoplasmacytic lymphoma
(LPL) is a relatively rare entity (incidence of 8
per 1 million; 1% of hematologic malignancies)
comprising of small B-cells, plasmacytoid lymphocytes, and plasma cells and is, as such, a
diagnosis of exclusion [14]. LPL is often accompanied by an IgM paraprotein and is indolent in
behavior with a prognosis similar to nodal MZL
but better than extranodal MZL. Since both
lymphomas are those of small B cells of postgerminal center derivation with many cases of
MZL showing plasmacytic differentiation, the
distinction between these two entities can be
challenging. More recently, mutations in
MYD88 have been described in 90% of LPL,
but these mutations have also been described
in cases of MZL [16]. Even in the hands of
experts, consensus is found in only about half
of cases. In some cases, the distinction is so
unclear as to generate a generic diagnosis of
small B-cell lymphoma with plasmacytic differentiation despite adequate immunohistochemical, flow cytometric, and clinical work up [17,
18].
In this study, we evaluate the pattern and extent of PRDM1 expression in lymphomas with
plasmacytic differentiation, namely marginal
zone lymphomas (MZL) and lymphoplasmacytic lymphoma (LPL).
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Materials and methods
Patient’s data
Permission for the study was granted by
the Washington University Human Studies
Committee. Sequentially archived snap
frozen shed flow cytometric samples with
the diagnosis of MZL or LPL were selected
from the Barnes-Jewish Hospital flow
cytometry archives from materials received between 2007-2010. All cases were
reviewed by 2 hematopathologists to confirm the diagnosis. For the immunohistochemical portion of the study, cases of MZL and LPL
from 2005-2008 were identified by searching
the Copath database of the Division of Anatomic Pathology and BJH databases. Cases of
nodal, extranodal, and splenic marginal zone
lymphoma were included. Normal control cases
included bone marrow samples which showed
no involvement by B cell lymphoma, reactive
lymph nodes, benign spleen, and benign tonsillar tissue.
Nucleic acid extraction and reverse transcriptase polymerase chain reaction
RNA extractions were performed by triazol
reagent. A DNase treatment was performed on
the RNA prior to reverse transcriptase-PCR
(RT-PCR). RT-PCR was performed using previously published primers for PRDM1-β [9]. This
generated cDNA that was run on a 4% agarose
gel. A one step RT-PCR method was used
according to manufacture protocol. The expected transcript length was 264 base pairs.
Different length bands or absent bands are
reported as abnormal. RT-PCR for beta-actin
was performed on all cases to ensure sample
RNA integrity.
PCR product purification and sequencing
PCR products from select abnormal cases with
different length bands were purified and
sequenced. PCR products from select cases
with normal bands were also purified and
sequenced to ensure target fidelity. This was
performed with standard manufacture protocol
for the Qiagen. Purified PCR products were
sequenced by traditional Sanger method.
Immunohistochemistry
Immunohistochemical staining was optimized
using an antibody directed to both PRDM1α
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Figure 1. A. Beta-actin control showing confirmed intact RNA for amplification in all samples. B. Abnormal bands
are seen in select lanes of LPL and MZL along with one normal control. Complete loss of PRDM1 transcript is identified in several lanes representing cases of MZL on sample gel (Follicular lymphoma, LPL = lymphoplasmacytic
lymphoma, MZL = marginal zone lymphoma, NL = normal control).

and PRDM1β due to the lack of a PRDM1 specific antibody. A BLIMP1 antibody (3H2-E8
clone, Novus Biologics) was optimized and antigen retrieval was performed using a CC1 standard protocol (1 mM EDTA pH 8.0). Staining was
performed on a BenchMark XT IHC/ISH Staining
Module, and detection was performed with XT
ultraView DAB v3. Slides were manually graded
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for percentage nuclear staining in the lymphocytes. Staining was performed at 1:4 dilution
(all cases). Cases with weaker or equivocal
staining were rerun at a 1:2 dilution (13 cases).
The higher of percentage staining between dilutions was adopted. In addition, two normal
bone marrow core biopsies in patients with a
history of plasma cell neoplasm and eight

Int J Clin Exp Pathol 2017;10(8):8610-8618

PRDM1 in MZL and LPL
Table 2. Summary of RT-PCR results and cytogenetic data

FL
LPL
MZL
NL
Other

Number
of cases
3
9
15
13
2

Wild-type (264 bp)
band only
3
5
5
9
0

Extra/abnormal
band
0
3
5
1
2

Complete
loss
0
1
5
0
0

Cytogenetics (#of cases)
t(14;18) (1)
Normal (2); Del11q21 and del 13 (1)
Normal (1)
---Normal (1)

(FL = Follicular Lymphoma, LPL = lymphoplasmacytic lymphoma, MZL = marginal zone lymphoma, NL = normal control).

benign tonsil specimens were included as controls. Five percent or less tumor staining was
considered negative.
Data analysis
The sequenced PCR product were aligned using
Basic Local Alignment Search Tool (BLAST®) to
interrogate for small deletions, insertions, substitutions, and transcripts of abnormal length.
Statistical analysis was performed using a twotailed Fischer t-test.
Results
Our search yielded 39 patient samples in total.
The samples included 27 malignant cases
comprising of 3 Follicular Lymphoma (FL), 9
LPL, 15 MZL (4 splenic MZL, 3 nodal MZL, 4
extra-nodal MZL, and 6 not further classified).
10 normal controls were initially evaluated,
comprising of 3 reactive lymph nodes, 1 splenomegaly spleen sample, and 6 bone marrows;
however two bone marrow cases were reclassified as indeterminate after review leaving 8 normal controls for comparison. In one case, a
minute plasma cell clone of unknown significance was detected. In the other case, multiple
lymphoid aggregates were noted in a patient
with a history of MZL. Though initially favored to
be benign, subsequent testing and involvement
at various other sites was suggestive of bone
marrow involvement. Demographic and specimen data is summarized in Table 1.
RT-PCR and sequencing
All follicular lymphomas showed a single 264
base pair band consistent with the wild-type
PRDM1 transcript (3/3). An extra abnormal
band was seen in 4 LPL cases, 3 MZL, and 1
normal (NL) case. Complete loss of the PRDM1
transcript (no band) was detected in 5 MZL
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cases and 1 LPL case (Figure 1). PCR and cytogenetic results are summarized in Table 2.
Overall, 67% of MZL and 44% of LPL showed
either loss or abnormal PRDM1-β transcript. All
cases that were initially diagnosed as normal
but subsequently reclassification showed abnormalities in PRDM1-β expression. PRDM1-β
abnormalities were more common in MZL and
LPL compared to normal cases (P=0.0043).
Sequencing of RT-PCR products from cases
with only the wild-type 264 base pair band confirmed wild-type PRDM1-β sequence at the
tested locus. Abnormal bands from a select
LPL and MZL case were sequenced which both
mapped to PRDM1 region with greater than
90% homology. A single normal case showed
an additional abnormal band. The forward read
did not map to PRDM1 and thus the product is
presumed to be non-specific.
Recurrent abnormalities involving the same
predicted splice site were also observed. A
recurrent splice site variant at position -44
and -45 of the PRDM1-β transcript lying in the
5’UTR region was observed in 3 of the cases (2
MZL and 1 LPL). Predictions regarding splicing
involving the promoter region were made based
on interrogating the splice site mutation with
two separate prediction software drosophila
and SIFT. However, the splice site mutation
does not appear to impact a change to the
protein.
Cytogenetic data was available for 5 of the
malignant cases. A t(14;18) was detected in
one follicular lymphoma. Del11q21 and del 13
were reported by an outside institution in one
case of LPL. Two other LPL cases and one MZL
case showed normal karyotype. No cases
showed a deletion involving 6q. Since the
cohort for PCR and IHC studies were different,
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Figure 2. Immunohistochemical staining with PRDM1: A. Marginal zone lymphoma (100×, Olympus BX51); B. Lymphoplasmacytic lymphoma (40×); C. Lymph node positive control (100×); D. Normal bone marrow negative control
(40×).

MZL cases (33%) but none of
the LPL cases 0/8 showed
positive staining for PRDM1
(P=0.116) (Figure 2). Though
Mean% lymphocyte
this was not statistically sigstaining in
nificant given the small sam(+) cases
ple size, a trend for increased
16% (range 10-25%)
immunostaining was seen.
0%
Both the bone marrow cores
0%
showed no staining (0/2). In
the benign lymph nodes, the
mantle zone lymphocytes were clearly negative while interfollicular plasma cells and a subset of germinal center cells showed positive
staining. Demographics and staining results
are summarized in Table 3.

Table 3. Summary of demographics and immunohistochemical
results for PRDM1 staining in marginal zone lymphoma and lymphoplasmacytic lymphoma
Percentage
PRDM1+
(≥ 5%)
71 (52-87) 6:6 33% (4/12)
61 (48-79) 6:2 0% (0/8)
63 (62-63) 2:0 0% (0/2)

Number Mean Age Sex
of cases (range) (F:M)
MZL
LPL
Normal BM

12
8
2

analysis was limited in that correlative comparisons between PCR, cytogenetics, and immunostaining were not possible.
Immunohistochemistry
A total of 20 lymphoma cases were available
for review comprising of 12 male and 8 female
patients with a median age of 66 years (range
48-87 years). Twelve of the cases were MZL
(60%) and 8 cases were LPL (40%). Four of 12
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Discussion
PRDM1 has previously been implicated in the
pathogenesis and treatment response of B-cell
lymphoid neoplasms such as Burkitt Lympho-
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ma (BL), DLBCL, MCL, and MM [19]. Furthermore PRDM1 has been shown to function as a
tumor suppressor in B cell lymphomas [18]. As
a key regulator of plasma cell differentiation in
B-cells, we sought to investigate the patterns of
expression and role of PRDM1-beta in B-cell
lymphomas associated with plasmacytic differentiation, namely MZL and LPL.
We found that in 67% and 44% of cases of MZL
and LPL, respectively, there was some type of
aberration of the PRDM1-β transcript. These
aberrations consisted of either complete loss
of the transcript seen in 33% and 11% of MZL
and LPL cases, respectively, or an abnormallysized transcript (33% for both). In these cases,
complete transcript loss may be the result of
deletions involving PRDM1 (located on 6q21,
Ensembl) or epigenetic mechanisms resulting
in silencing of PRDM1 expression. Though
available cytogenetic data was limited, no loss
of 6q was detect in any of the cases implying
the presence of a microdeletion. Cryptic deletions of 6q21 have been previously reported in
MZL (14%-16% of cases) and were associated
with a switch to high grade histology (predominant large cell or blast component) [20]. In fact,
del6q has been identified as one of the predominant aberrations in splenic MZL (11%)
though an association with survival has not
been described [21, 22]. With regards to lymphoplasmacytic lymphoma, del6q has been
cited as the most frequent copy number alteration in Waldenstrom macroglobulinemia (WM)
with rates of detection based on various methodologies (conventional cytogenetics, FISH,
array CGH, SNP) ranging from 22% to 42% [23].
In WM, del6q may be a poor prognostic factor
[24]. There is variability in the minimal deleted
region due to involvement of large fragments of
6q. Putative tumor suppressor genes in this
region include TNFAIP3 and PRDM1 [24, 25].
The frequency of PRDM1 loss in our study is
lower than that cited in the literature for LPL,
though this may be due to our small sample
size. Furthermore, since primers targeted only
the beta transcript (not alpha), it is possible
that we are underestimating the loss PRDM1
mRNA transcripts in this study. Based on frequent loss in MZL, PRDM1 may serve as a rational candidate gene for disease pathogenesis in
MZL as well as LPL. Functional and animal studies with knock-out models, are likely to aid in
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clarifying PRDM1’s precise role in lymphomagenesis.
Deletion in 6q is a known common abnormality
seen in lymphoid malignancies [26]. While the
loss of PRDM1 may be responsible for the
pathogenesis in some of the cases with 6q
deletion, other mechanisms are likely at play
given that nearly half of cases will not demonstrate deletion of 6q. Whole genome survey for
copy number alterations may have shed light in
this regard, but remained a limitation for this
study due to the lack of additional material. In
ocular adnexal marginal zone B cell lymphoma,
TNFAIP3 was identified as the target gene in
cases of loss at adjacent 6q23.3-q24.1 loci
[27]. A negative regulator of nuclear factor-kappa B (NF-kappaB), TNFAIP3 was deleted in
other lymphoid malignancies such as DLBCL
and MCL [28]. In DLBCL, deletions of either
PRDM1 or TNFAIP3 were seen, but not both,
would be deleted in a homozygous manner
[29]. The possibility of functional synergism
between PRDM1 and the TNFAIP3 gene product may also be considered in MZL and LPL [5].
In many of the cases in our cohort, an abnormally sized band was identified rather than complete loss of the transcript. Sanger sequencing identified various mutations to account for
the change in transcript size including single
base pair deletions and single base pair substitutions. Interestingly, a recurrent splice site
variant was identified affecting the promoter
region in the 5’UTR of the PRDM1 transcript. The functional significance of these genetic alterations are unclear without in vitro studies, but one may postulate that alternative
splicing may result in a qualitative defect of the
translated protein providing a mechanism for
‘functional deletion’. This proposes a possible
mechanism leading to down regulation of
PRDM1 in these B cell lymphomas.
In this study, PRDM1 staining (>5%) was more
frequently positive in MZL than LPL. While
absent staining was seen in LPL, loss by immunohistochemistry did not correlate with loss of
the PRDM1 transcript in our PCR experiments.
This may be the result of non-specificity of the
PRDM1 antibody derived from the 3H2-E8 cell
line which was raised using murine PRDM-1
residues 199-409. The antibody did not demonstrate specificity for the beta transcript like
the primer used for RT-PCR. The use of an
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aptamer with specificity for the beta variant
may circumvent this limitation. Furthermore,
despite titration of antibody at various dilutions, most cases showed only a light blush of
staining in positive cells in order to obtain low
background, making grading of staining in the
lymphoma cases subjective. Higher concentration of antibody may have demonstrated positivity in LPL cases, but at the cost of increasing
non-specific background staining making reliable grading infeasible. Other studies, which
have used immunohistochemistry, have shown
PRDM1 expression in LPL plasma cells appeared to be lower in comparison to marginal
zone lymphoma and myeloma, however they
were not able to achieve statistical significance
[30].
Overall, this study implicates altered PRDM1
expression in the pathogenesis of lymphomas
with plasmacytic differentiation, namely LPL
and MZL. This is congruent with gene expression studies, which have shown lower PRDM1
expression in lymphoplasmacytic lymphoma
[31]. Alterations in PRDM1 are biologically
rational in this regard, considering that loss of a
factor driving B-cell differentiation to plasma
cells could well account for absence of full plasmacytic differentiation in the B-cells that comprise these neoplasms. FISH or sequencing of
cases with total PRDM1 loss may help differentiate between epigenetic mechanisms versus
deletions in these cases. Importantly, it will be
useful to analyze clinical outcomes in patients
with PRDM1 aberrations as well as investigate
propensity to progress to DLBCL so as to determine the clinical significance of our findings.
Finally, in-vitro and murine models may provide
clarification with regards to the true biologic
role of PRDM1 in low-grade lymphomas with
plasmacytic differentiation.
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